JP6450688B2 - 呼吸器合胞体ウイルスｆタンパク質エピトープ - Google Patents

呼吸器合胞体ウイルスｆタンパク質エピトープ Download PDF

Info

Publication number
JP6450688B2
JP6450688B2 JP2015556154A JP2015556154A JP6450688B2 JP 6450688 B2 JP6450688 B2 JP 6450688B2 JP 2015556154 A JP2015556154 A JP 2015556154A JP 2015556154 A JP2015556154 A JP 2015556154A JP 6450688 B2 JP6450688 B2 JP 6450688B2
Authority
JP
Japan
Prior art keywords
protein
rsv
fusion
seq
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015556154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016508503A (ja
JP2016508503A5 (https=
Inventor
ウルブラント，ナンシー
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2016508503A publication Critical patent/JP2016508503A/ja
Publication of JP2016508503A5 publication Critical patent/JP2016508503A5/ja
Application granted granted Critical
Publication of JP6450688B2 publication Critical patent/JP6450688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2015556154A 2013-02-01 2014-01-31 呼吸器合胞体ウイルスｆタンパク質エピトープ Active JP6450688B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361759664P 2013-02-01 2013-02-01
US61/759,664 2013-02-01
US201361783380P 2013-03-14 2013-03-14
US61/783,380 2013-03-14
PCT/US2014/014054 WO2014121021A1 (en) 2013-02-01 2014-01-31 Respiratory syncytial virus f protein epitopes

Publications (3)

Publication Number Publication Date
JP2016508503A JP2016508503A (ja) 2016-03-22
JP2016508503A5 JP2016508503A5 (https=) 2017-02-23
JP6450688B2 true JP6450688B2 (ja) 2019-01-09

Family

ID=51262966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015556154A Active JP6450688B2 (ja) 2013-02-01 2014-01-31 呼吸器合胞体ウイルスｆタンパク質エピトープ

Country Status (17)

Country Link
US (1) US10016496B2 (https=)
EP (1) EP2950886B1 (https=)
JP (1) JP6450688B2 (https=)
CN (1) CN105073196B (https=)
AU (1) AU2014212268B2 (https=)
CA (1) CA2900110A1 (https=)
CY (1) CY1122937T1 (https=)
DK (1) DK2950886T3 (https=)
ES (1) ES2778899T3 (https=)
HR (1) HRP20200404T1 (https=)
LT (1) LT2950886T (https=)
PL (1) PL2950886T3 (https=)
PT (1) PT2950886T (https=)
RS (1) RS60056B1 (https=)
SI (1) SI2950886T1 (https=)
SM (1) SMT202000145T1 (https=)
WO (1) WO2014121021A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
EP4353316A3 (en) 2014-01-15 2024-08-21 Medimmune Limited Rsv-specific antibodies and functional parts thereof
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
JP2020503843A (ja) * 2016-10-21 2020-02-06 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
CN110035771B (zh) 2016-10-21 2024-03-08 阿迪马布有限责任公司 抗呼吸道合胞病毒抗体及其产生和使用方法
WO2018075954A2 (en) * 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
TWI683826B (zh) * 2016-11-22 2020-02-01 國立臺灣大學 重組ｒｓｖ抗原
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
CN111208307B (zh) * 2020-04-21 2020-07-17 上海普铭生物科技有限公司 一种与参照分子具有相同或不同的靶蛋白结合的分子的筛选方法
CN119462859A (zh) * 2023-08-09 2025-02-18 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、疫苗及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US20020018780A1 (en) 2000-05-25 2002-02-14 Scott Koenig Epitope-based vaccine for respiratory syncytial virus F-protein
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2009128949A2 (en) * 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
EP2408477A4 (en) 2009-03-16 2013-03-27 Sanofi Pasteur Biologics Llc REPLICATION DEFECTS FLAVIVIRUS VACCINE VACCINATORS AGAINST RESPIRATORY SYNZYTIAL VIRUS
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011043643A1 (en) 2009-10-06 2011-04-14 Medimmune Ltd Rsv-specific binding molecule
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
FI2970398T3 (fi) 2013-03-13 2024-08-06 Us Health Rsv f -prefuusioproteiineja ja niiden käyttö
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions

Also Published As

Publication number Publication date
DK2950886T3 (da) 2020-03-23
JP2016508503A (ja) 2016-03-22
EP2950886A4 (en) 2016-09-07
CA2900110A1 (en) 2014-08-07
WO2014121021A1 (en) 2014-08-07
SI2950886T1 (sl) 2020-06-30
ES2778899T3 (es) 2020-08-12
CN105073196A (zh) 2015-11-18
PT2950886T (pt) 2020-03-26
LT2950886T (lt) 2020-07-10
EP2950886A1 (en) 2015-12-09
HRP20200404T1 (hr) 2020-06-12
PL2950886T3 (pl) 2020-06-01
US10016496B2 (en) 2018-07-10
CN105073196B (zh) 2020-04-07
EP2950886B1 (en) 2019-12-18
RS60056B1 (sr) 2020-04-30
US20150366960A1 (en) 2015-12-24
SMT202000145T1 (it) 2020-05-08
AU2014212268A1 (en) 2015-08-20
AU2014212268B2 (en) 2018-07-19
CY1122937T1 (el) 2020-10-14

Similar Documents

Publication Publication Date Title
JP6450688B2 (ja) 呼吸器合胞体ウイルスｆタンパク質エピトープ
JP6285469B2 (ja) 呼吸器合胞体ウイルスの熱安定な融合前ｆタンパク質オリゴマーおよび免疫組成物におけるその使用
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
Rigter et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles
CN107847580B (zh) 针对rsv的疫苗
US20110318376A1 (en) Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
JP6016799B2 (ja) 呼吸器合胞体ウイルスワクチン
US11248039B2 (en) Immunoglobulin single variable domain antibody against RSV prefusion F protein
EP1793850A2 (en) Antibodies against and methods for producing vaccines for respiratory syncytial virus
TW202306967A (zh) 經改良之冠狀病毒疫苗
CN118725053A (zh) 呼吸道合胞病毒融合前f蛋白突变体及其应用
US9499590B2 (en) Antibodies against and methods for producing vaccines for respiratory syncytial virus
CN114163504A (zh) SARS-CoV-2 S蛋白RBD区中和表位肽及其应用
CN105542003B (zh) 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
CN116847881A (zh) 经改良的冠状病毒疫苗
US10377798B2 (en) Recombinant respiratory syncytial virus G protein fragments
CN116472278A (zh) 与埃博拉病毒疫苗相关的组合物和方法
CN104628850B (zh) Rsv-特异性结合分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181210

R150 Certificate of patent or registration of utility model

Ref document number: 6450688

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250